Free Trial

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
$83.65 -0.71 (-0.84%)
Closing price 10/2/2025 04:00 PM Eastern
Extended Trading
$83.96 +0.30 (+0.36%)
As of 10/2/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for AZN.

Consensus Price Target

$86.00
2.81% Upside
According to the 4 analysts' twelve-month price targets for AstraZeneca, the average price target is $86.00. The highest price target for AZN is $97.00, while the lowest price target for AZN is $75.00. The average price target represents a forecasted upside of 2.81% from the current price of $83.65.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
10/3/24 to 10/3/25
1 Month Ago
9/3/24 to 9/3/25
3 Months Ago
7/5/24 to 7/5/25
1 Year Ago
10/4/23 to 10/3/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$86.00$86.00$85.00$89.75
Forecasted Upside2.81% Upside4.74% Upside22.13% Upside15.17% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.77
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.81% Upside2,469.02% Upside10.96% Upside
News Sentiment Rating
Positive News

See Recent AZN News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
7/9/2025Berenberg Bank
2 of 5 stars
Luisa Hector
Not Rated
Set Target$97.00+37.02%
4/15/2025BNP Paribas
4 of 5 stars
P. Verdult
Not Rated
Initiated CoverageOutperform$75.00+11.09%
2/13/2025UBS Group
4 of 5 stars
M. Weston
Not Rated
UpgradeNeutralBuy
2/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOverweight
11/6/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeSellHold
9/11/2024Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy
8/12/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$90.00 ➝ $95.00+16.29%
6/24/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$80.00 ➝ $85.00+10.72%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$97.00+27.50%
4/26/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$80.00 ➝ $82.00+8.70%
1/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold
12/18/2023HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:12 AM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 29, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca:

  • AstraZeneca has shown significant growth in institutional investment, with several firms increasing their stakes recently, indicating strong confidence in the company's future performance.
  • The stock has a current price around $76, which is near its one-year high, suggesting potential for further appreciation as market conditions improve.
  • Analysts have rated AstraZeneca with a "Moderate Buy" consensus, reflecting positive sentiment and expectations for the company's stock performance.
  • The company has a solid market capitalization of approximately $236 billion, which provides stability and resources for future growth initiatives.
  • AstraZeneca's recent developments in its product pipeline and ongoing research efforts position it well in the competitive pharmaceutical market, potentially leading to new revenue streams.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca for these reasons:

  • The stock has experienced fluctuations, with a recent decline of about 1% in trading, which may indicate volatility and uncertainty in the short term.
  • AstraZeneca's debt-to-equity ratio is 0.55, which, while manageable, suggests that the company has a moderate level of debt that could impact financial flexibility.
  • Despite positive analyst ratings, there is still a risk of market corrections that could affect stock prices, especially in the pharmaceutical sector.
  • The company's quick ratio of 0.67 indicates that it may face challenges in meeting short-term liabilities, which could raise concerns for investors focused on liquidity.
  • Competition in the pharmaceutical industry is intense, and AstraZeneca must continuously innovate to maintain its market position, which can be a significant challenge.

AZN Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $86.00, with a high forecast of $97.00 and a low forecast of $75.00.

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 2.81% based on their 12-month stock forecasts.

AstraZeneca has been rated by research analysts at Berenberg Bank in the past 90 days.

Analysts like AstraZeneca less than other "medical" companies. The consensus rating score for AstraZeneca is 2.75 while the average consensus rating score for "medical" companies is 2.77. Learn more on how AZN compares to other companies.


This page (NASDAQ:AZN) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners